Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
Pharvaris N.V. Chief Medical Officer Lu Peng reported a series of option exercises and related share sales. On June 25–26, 2026, she exercised stock options covering 29,700 shares of common stock at a $2.59 exercise price and sold 29,700 shares in open-market transactions under a Rule 10b5-1 trading plan using cashless exercises. Reported weighted average sale prices were about $34.45, $35.09, and $34.00, each reflecting multiple trades within narrow price ranges. Following these transactions, Peng holds 65,631 shares of Pharvaris common stock directly.
PHVS filing a Form 144 reporting proposed sale of 6,888 shares of Common (listed as Founders Shares) by an affiliated holder. The excerpt also lists completed 10b5-1 sales by Hans H. Schikan totaling specific trades on 04/22/2026, 04/23/2026, 04/29/2026, 04/30/2026, and 06/25/2026.
PHVS-related holders reported planned dispositions of Common stock under Rule 144/10b5-1. The filing lists multiple 10b5-1 sales by Anne Simonne J. Lesage and Graymatters Consulting on 04/30/2026 and 06/25/2026, with per-trade share counts and proceeds shown in the filing.
PHVS filed a Form 144 reporting proposed sales and an option exercise. The filing lists an exercise of stock options for 8,300 shares on 06/29/2026 for cash. It also lists multiple 10b5-1 sales by Anne Simonne J. Lesage and Graymatters Consulting on dates in April and June 2026, including transactions of 21,700 shares and 19,200 shares on 04/30/2026.
PENG LU reported multiple dispositions of Common Stock via Rule 10b5-1 sales and an exercise-related sale in late April through June 2026. The filing lists individual 10b5-1 sales on 04/22/2026, 04/29/2026, 04/30/2026, 05/01/2026, 06/18/2026, and 06/25/2026, and an Exercise of Stock Options reported on 06/26/2026.
The excerpt shows transaction line items with per‑trade share counts and proceeds (for example, 15,000 shares for $518,985 on 06/25/2026 and 14,166 shares for $427,417.97 on 05/01/2026). These entries are presented as broker-handled sales through Morgan Stanley Smith Barney LLC.
PHVS files a Form 144 reporting proposed sale of 15,000 shares of Common Stock. The filing states the shares relate to an exercise of stock options and are to be sold for cash on 06/25/2026. The excerpt also lists prior 10b5-1 sales in April–June 2026 totaling multiple transactions, including 14,166 and 15,000 share sales on 05/01/2026 and 04/30/2026, respectively.
PHVS filed a Form 144 reporting sales of Common Stock under prearranged 10b5-1 plans. The filing lists broker-dealer Morgan Stanley Smith Barney LLC and shows multiple 10b5-1 sales by Anne Simonne J. Lesage and Graymatters Consulting on 04/22/2026, 04/23/2026, 04/29/2026, and 04/30/2026
Examples shown include 21,700 shares sold by Lesage on 04/30/2026 for $656,550.86 and 19,200 shares sold by Graymatters Consulting on 04/30/2026 for $580,909.44. Shares outstanding are listed as 65,210,590 shares as of 06/25/2026.
PHVS filed a Form 144 reporting a proposed sale of 2,300 shares of Common Stock in connection with the exercise of stock options scheduled for 06/25/2026. The filing lists prior 10b5-1 plan sales in April 2026 by two related holders, including multiple trades on 04/30/2026 and earlier dates.
The notice names a broker-dealer, Morgan Stanley Smith Barney LLC, and records cash settlement. The filing is administrative disclosure of an intended resale under Rule 144 and describes recent 10b5-1 sales by Anne Simonne J. Lesage and Graymatters Consulting.
PHVS filed a Form 144 reporting proposed/resale sales of Common Stock by a selling holder. The excerpt lists multiple 10b5-1 programmed sales by Hans H. Schikan totaling reported trades on 04/22/2026, 04/23/2026, 04/29/2026, and 04/30/2026.
The transactions include 7,000 shares on 04/22/2026 and 29,070 shares on 04/30/2026, with gross proceeds shown in the excerpt for each trade. The filing also references 2,400 Founders Shares in the securities table.